ADC Therapeutics' Zynlonta (loncastuximab tesirine-lpyl) Receives the US FDA's Approval for the Treatment of R/R Diffuse Large B-Cell Lymphoma
Shots:
- The approval is based on data from the P-II LOTIS-2 trial involves assessing Zynlonta in adults with r/r DLBCL following two or more prior lines of systemic therapy
- Results: ORR (48.3%); CRR (24.1)- PR (24.1%)- and mDoR in 70 responders (10.3mos.) with a median time to response of 1.3 mos. The therapy will be commercially available in the US imminently
- Zynlonta is the 1st CD19-targeted ADC approved as a monothx. for adult patients with r/r DLBCL. The company has launched the patient support program to provide financial assistance- education- and other resources for patients who are prescribed the therapy
Ref: Businesswire | Image: ADC Therapeutics
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
